Hyloris Pharmaceuticals (LTS:0AB6) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
59 GF Score
Price €4.71
GF Value €9.35
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

LTS:0AB6
59GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.71 is trading 49.6% below its estimated GF Value™ of €9.35.

Key valuation signals for LTS:0AB6:

  • FFO per Share:
  • GF Value™: €9.35 vs. price of €4.71 (49.6% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
59GF Score

Get the complete analysis for LTS:0AB6

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.71
Price
€9.35
GF Value